Current therapy of ulcerative colitis in children

Bibliography

• EHLIN A, MONTGOMERY S, EKBOM A, POUNDER R, WAKEFIELD A: Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut (2003) 58:1117–1121.
   Google Scholar
• SAWCZENKO A, SANDHU BK, LOGAN RF et al.: Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet (2001) 357:1093–1094.
   PubMed Web of Science ®Google Scholar
• •A prospective study of the epidemiology of IBD in children in the UK.
   Google Scholar
• WATTS DA and SATSANGI J: The genetic jigsaw of inflammatory bowel disease. Gut (2002) 50\(Suppl. 3):III31-III36.
   Google Scholar
• •A comprehensive review of the genetic loci linked with IBD.
   Google Scholar
• HYAMS JS, DAVIS P, GRANCHER K et al.: Clinical outcome of ulcerative colitis in children. Pediatr. (1996) 129:81–88.
   Google Scholar
• ESCHER JC, TAMINIAU JA, NIEUWENHUIS EE, BULLER HA, GRAND RJ: Treatment of inflammatory bowel disease in childhood: best available evidence. Inflarnm. Bowel. Dis. (2003) 9:34–58.
   PubMedGoogle Scholar
• ••Evidence for IBD treatments in childrenare reviewed, highlighting a lack of randomised, controlled trials.
   Google Scholar
• SPRAY C, DEBELLE GD, MURPHY MS: Current diagnosis, management and morbidity in paediatric inflammatory bowel disease. Acta Paediatrica (2001) 90:400–405.
   PubMed Web of Science ®Google Scholar
• •Data illustrating the presentation of IBD in children.
   Google Scholar
• BEATTIE RM, WALKER-SMITH JA, MURCH SH: Indications for investigation of chronic gastrointestinal symptoms. Arch. Dis. Child. (1995) 73:354–355.
   PubMed Web of Science ®Google Scholar
• KHAN K, SCHWARZENBERG SJ, SHARP H, GREENWOOD D, WEISDORF-SCHINDELE S: Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm. Bowel. Dis. (2002) 8:325–329.
   PubMed Web of Science ®Google Scholar
• RUEMMELE FM, TARGAN SR, LEVY G et al: Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 115:822–829.
   PubMed Web of Science ®Google Scholar
• JOOSSENS S, REINISCH W,VERMEIRE S et al: The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 122:1242–1247.
   PubMed Web of Science ®Google Scholar
• WASHINGTON K, GREENSON JK, MONTGOMERY E et al.: Histopathology of ulcerative colitis in initial rectal biopsy in children. Am. I Slug. Pathol. (2002) 26:1441–1449.
   PubMed Web of Science ®Google Scholar
• KUNDHAL PS, STORMON MO, ZACHOS M et al.: Gastral antral biopsy in the differentiation of pediatric colitides. Am. J. Gastroenterol. (2003) 98:557–561.
   PubMed Web of Science ®Google Scholar
• ABDULLAH BA, GUPTA SK, CROFFIE JM et al: The role of esophagogastroduodenoscopy in the initial evaluation of childhood inflammatory bowel disease: a 7-year study. Pediatr. Gastroenterol. Nutr. (2002) 35:636–640.
   PubMedGoogle Scholar
• HABER HP, BUSCH A, ZIEBACH R et al.: Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. Ultrasound Med. (2002) 21:375–382.
   PubMedGoogle Scholar
• ••Ultrasound scanning as a useful adjunct inthe assessment of colitis in children.
   Google Scholar
• BARABINO A, GATTORNO M, CABRIA M et al.: 99mTc-white cell scanning to detect gut inflammation in children with inflammatory bowel diseases or spondyloarthropathies.Clin. Exp. Rheumatol. (1998)16:327–334.
   Google Scholar
• BRUNO I, MARTELOSSI S, GEATTI 0 et al.: Antigranulocyte monoclonal antibody immunoscintigraphy in inflammatory bowel disease in children and young adolescents. Acta Paediatr. (2002) 91:1050–1055.
   Google Scholar
• CHARRON M, DEL ROSARIO FJ, KOCOSHIS SA: Pediatric inflammatory bowel disease: assessment with scintigraphy with 99mTc white blood cells. Radiology (1999) 212:507–513.
   PubMed Web of Science ®Google Scholar
• GHOSH S, SHAND A, FERGUSON A: Ulcerative colitis. Br. Med. (2000) 320:1119–1123.
   PubMed Web of Science ®Google Scholar
• BEATTIE RM, NICHOLLS SW, DOMIZIO P, WILLIAMS CB, WALKER-SMITH JA: Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. Pediatr. Gastroenterol. Nutr. (1996) 22:373–379.
   PubMedGoogle Scholar
• OTLEY A, SMITH C, NICHOLAS D et al.: The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. Pediatr. Gastroenterol. Nutr. (2002) 35:557–563.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND L, MACDONALD JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev (2003) CD000543.
   Google Scholar
• FERRY GD, KIRSCHNER BS, GRAND RJ et al.: Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. Pediatr. Gastroenterol. Nutr. (1993) 17:32–38.
   PubMedGoogle Scholar
• PRUITT R, HANSON J, SAFDI M et al: Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am. Gastroenterol. (2002) 97:3078–3086.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND L, ROTH D, BECK P, MAY G, MAKIYAMA K: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev (2002) CD000544.
   Google Scholar
• BARDEN L, LIPS ON A, PERT P and WALKER-SMITH JA: Mesalazine in childhood inflammatory bowel disease. Aliment. Pharmacol. Ther. (1989) 3:597–603.
   PubMedGoogle Scholar
• ARDIZZONE S, PORRO GB: Comparative tolerability of therapies for ulcerative colitis. Drug Sal (2002) 25:561–582.
   PubMed Web of Science ®Google Scholar
• ALSTEAD EM, NELSON-PIERCY C: Inflammatory bowel disease in pregnancy. Gut (2003) 52:159–161.
   PubMed Web of Science ®Google Scholar
• RANSFORD RA, LANGMAN MJ: Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut (2002) 51:536–539.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB: Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther. (2003) 17:29–42.
   PubMed Web of Science ®Google Scholar
• JARNEROT G, ROLNY P, SANDBERG-GERTZEN H: Intensive intravenous treatment of ulcerative colitis. Gastroenterology (1985) 89:1005–1013.
   PubMed Web of Science ®Google Scholar
• HANAUER SB and PRESENT DH: The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol. Disord. (2003) 3:81–92.
   PubMedGoogle Scholar
• LOFBERG R, DANIELSSON A, SUHR 0 et al.: Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology (1996) 110:1713–1718.
   Google Scholar
• KELLER R, STOLL R, FOERSTER EC, GUTSCHE N, DOMSCHKE W: Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. liment. Pharmacol. Ther: (1997) 11:1047–1052.
   PubMed Web of Science ®Google Scholar
• CAMPIERI M, ADAMO S, VALPIANI D et al.: Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment. Pharmacol. Ther. (2003) 17:1471–1480.
   PubMed Web of Science ®Google Scholar
• TURUNEN UM, FARKKILA MA, HAKALA K et al: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology (1998) 115:1072–1078.
   PubMed Web of Science ®Google Scholar
• GREENBLOOM SL, STEINHART AH, GREENBERG GR: Combination ciprofloxacin and metronidazole for active Crohn's disease. Can. Gastroenterol. (1998) 12:53–56.
   PubMed Web of Science ®Google Scholar
• BALL P, MANDELL L, NIKI Y, TILLOTSON G: Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Sal (1999) 21:407–421.
   PubMed Web of Science ®Google Scholar
• DUBINSKY MC, YANG H, HASSARD PV et al: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 122:904–915.
   PubMed Web of Science ®Google Scholar
• ••Exploring the link between drugmetabolism and efficacy for thioptirines.
   Google Scholar
• GEORGE J, PRESENT DH, POU R, BODIAN C and RUBIN PH: The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am. J. Gastroenterol. (1996) 91:1711–1714.
   PubMed Web of Science ®Google Scholar
• ARDIZZONE S, MOLTENI P, IMBESI V et al.: Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J. Clin. Gastroenterol. (1997) 25:330–333.
   PubMed Web of Science ®Google Scholar
• HAWTHORNE AB, LOGAN RF, HAWKEY CJ et al: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br. Med. (1992) 305:20–22.
   PubMed Web of Science ®Google Scholar
• VERHAVE M, WINTER HS and GRAND RJ: Azathioprine in the treatment of children with inflammatory bowel disease. Pediatr. (1990) 117:809–814.
   Google Scholar
• KADER HA, MASCARENHAS MR, PICCOLI DA, STOUFFER NO, BALDASSANO RN: Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. Pediatr. Gastroenterol. Nutt: (1999) 28:54–58.
   Google Scholar
• BARABINO A, TORRENTE F, VENTURA A et al: Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment. Pharmacol. Ther. (2002) 16:1125–1130.
   PubMed Web of Science ®Google Scholar
• DUBINSKY MC, LAMOTHE S, YANG HY et al: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology(2000) 118:705–713.
   PubMed Web of Science ®Google Scholar
• SCHWAB M, SCHAFFELER E, MARX C et al: Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics (2002) 12:429–436.
   PubMedGoogle Scholar
• ••TPMT genotype influences thehaematological but not gastrointestinal toxicity of azathioprine.
   Google Scholar
• NIELSEN OH, VAINER B, RASK-MADSEN J: Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol. Ther. (2001) 15:1699–1708.
   PubMed Web of Science ®Google Scholar
• LOWRY PW, FRANKLIN CL, WEAVER AL et al: Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut (2001) 49:656–664.
   PubMedGoogle Scholar
• KIRSCHNER BS: Safety of azathioprineand 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology (1998) 115:813–821.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ J, GRANCHER K, MANDEL F, DAUM F: Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Am. Gastroenterol. (1993) 88:44–48.
   Google Scholar
• FUENTES D, TORRENTE F, KEADY S et al: High-dose azathioprine in children with inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 17:913–921.
   PubMedGoogle Scholar
• FRASER AG, ORCHARD TR and JEWELL DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut (2002) 50:485–489.
   PubMed Web of Science ®Google Scholar
• OREN R, ARBER N, ODES S et al: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology (1996) 110:1416–1421.
   PubMed Web of Science ®Google Scholar
• PAOLUZI OA, PICA R, MARCHEGGIANO A et al.: Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment. Pharmacol. Ther. (2002) 16:1751–1759.
   PubMed Web of Science ®Google Scholar
• LICHTIGER S, PRESENT DH: Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet (1990) 336:16–19.
   PubMed Web of Science ®Google Scholar
• LOFTUS CG, LOFTUS EV Jr, SANDBORN WJ: Cyclosporin for refractory ulcerative colitis. Gut (2003) 52:172–173.
   PubMed Web of Science ®Google Scholar
• TREEM WR, COHEN J, DAVIS PM, JUSTINICH CJ, HYAMS JS: Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis. Colon Rectum (1995) 38:474–479.
   Google Scholar
• BARABINO A, TORRENTE F, CASTELLANO E et al: The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. Aliment. Pharmacol. Ther. (2002) 16:1503–1507.
   PubMedGoogle Scholar
• ••Defining the role for cydosporin insevere colitis in children - recent clinical experiences.
   Google Scholar
• RAMAKRISHNA J, LANGHANS N, CALENDA K, GRAND RJ, VERHAVE M: Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. Pediatr. Gastroenterol Nuti: (1996) 22:296–302.
   Google Scholar
• BARABINO A, CASTELLANO E, GANDULLIA P, BISCALDI E: A girl with severe fistulizing Crohn's disease. Dig. Liver Dis. (2000) 32:792–794.
   PubMedGoogle Scholar
• ROSENCRANTZ R, MOON A, RAYNES H, SPIVAK W: Cyclosporine-Induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors. Am. Gastroenterol (2001) 96:2778–2782.
   PubMed Web of Science ®Google Scholar
• PODOLSKY DK: Inflammatory bowel disease. N Engl. Med. (2002) 347:417–429.
   PubMed Web of Science ®Google Scholar
• WIRTZ S, NEURATH MF: Gene transfer approaches for the treatment of inflammatory bowel disease. Gene Ther: (2003) 10:854–860.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of future prospects forbiological therapies in IBD.
   Google Scholar
• BOUSVAROS A, KIRSCHNER BS, WERLIN SL et al.: Oral tacrolimus treatment of severe colitis in children. Pediatr. (2000) 137:794–799.
   Web of Science ®Google Scholar
• BAUMGART DC, WIEDENMANN B, DIGNASS AU: Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment. Pharmacol Ther. (2003) 17:1273–1281.
   PubMed Web of Science ®Google Scholar
• FELLERMANN K, TANKO Z, HERRLINGER KR et al: Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm. Bowel. Dis. (2002) 8:317–324.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 359:1541–1549.
   PubMed Web of Science ®Google Scholar
• SERRANO MS, SCHMIDT-SOMMERFELD E, KILBAUGH TJ et al.: Use of infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. (2001) 35:823–828.
   PubMed Web of Science ®Google Scholar
• MAMULA P, MARKOWITZ JE, BROWN KA et al.: Infliximab as a novel therapy for pediatric ulcerative colitis. Pediatr. Gastroenterol Nutr. (2002) 34:307–311.
   PubMed Web of Science ®Google Scholar
• ••Suggests a role for anti-TNF antibodiesin UC.
   Google Scholar
• ACTIS GC, BRUNO M, PINNA-PINTOR M, ROSSINI FP, RIZZETTO M: Infliximab for treatment of steroid-refractory ulcerative colitis. Dig. Liver Dis. (2002) 34:631–634.
   PubMedGoogle Scholar
• GORNET JM, COUVE S, HASSANI Zet al.: Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment. Pharmacol Ther. (2003) 18:175–181.
   Google Scholar
• PROBERT CS, HEARING SD, SCHREIBER S et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 52:998–1002.
   PubMed Web of Science ®Google Scholar
• FARRELL RJ, ALSAHLI M, JEEN YT et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology (2003) 124:917–924.
   PubMed Web of Science ®Google Scholar
• KUGATHASAN S, LEVY MB, SAEIAN K et al.: Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am. Gastroenterol (2002) 97:1408–1414.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ: Preventing antibodies toinfliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology (2003) 124:1140–1145.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB: Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am. J. Gastroenterol (2002) 97:2962–2972.
   PubMed Web of Science ®Google Scholar
• CREED TJ, NORMAN MR, PROBERT CS et al: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol Ther: (2003) 18:65–75.
   Google Scholar
• VAN ASSCHE G, DALLE I, NOMAN M et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am. J. Gastroentera (2003) 98:369–376.
   PubMed Web of Science ®Google Scholar
• SINHA A, NIGHTINGALE J, WEST KP, BERLANGA-ACOSTA J, PLAYFORD RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl. Med. (2003) 349:350–357.
   PubMed Web of Science ®Google Scholar
• ••The first description of a growth factortherapy for UC.
   Google Scholar
• SHIMOYAMA T, SAWADA K, HIWATASHI N et al: Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerativecolitis: a multicenter study. ]: Clin. Apheresis. (2001) 16:1–9.
   PubMed Web of Science ®Google Scholar
• TOMOMASA T, KOBAYASHI A, KANEKO H et al: Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig. Dis. Sci. (2003) 48:750–754.
   PubMed Web of Science ®Google Scholar
• GIONCHETTI P, RIZZELLO F, HELWIG U et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 124:1202–1209.
   PubMed Web of Science ®Google Scholar
• ••Probiotics and preventing pouchitis.
   Google Scholar
• GUSLANDI M, GIOLLO P and TESTONI PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. Gastroenterol Hepatol (2003) 15:697–698.
   PubMed Web of Science ®Google Scholar
• VENTURI A, GIONCHETTI P, RIZZELLO F et al.: Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol Ther: (1999) 13:1103–1108.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA H, AKEDO I, UMESAKI Y et al.: Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. ] Am. Coll. Nutr: (2003) 22:56–63.
   PubMed Web of Science ®Google Scholar
• VERNIA P, ANNESE V, BRESCI G et al:Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur: I Clin. Invest. (2003) 33:244–248.
   Google Scholar
• HALLERT C, BJORCK I, NYMAN M et al.: Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflarnm. Bowel. Dis. (2003) 9:116–121.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-BANARES F, HINOJOSA J, SANCHEZ-LOMBRANA JL et al.: Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am. I Gastroenterol (1999) 94:427–433.
   Google Scholar
• MARSHALL JK, IRVINE EJ: Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am. J. Gastroenterol (2000) 95:1628–1636.
   PubMed Web of Science ®Google Scholar
• MARSHALL JK, IRVINE EJ: Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut (1997) 40:775–781.
   PubMed Web of Science ®Google Scholar
• SCHOON EJ, BLOK BM, GEERLING BJ et al.: Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology (2000) 119:1203–1208.
   PubMed Web of Science ®Google Scholar
• BJARNASON I, MACPHERSON A, MACKINTOSH C et al.: Reduced bone density in patients with inflammatory bowel disease. Gut (1997) 40:228–233.
   PubMed Web of Science ®Google Scholar
• DINCA M, FRIES W, LUISETTO G et al.: Evolution of osteopenia in inflammatory bowel disease. Am. J. Gastroenterol (1999) 94:1292–1297.
   PubMed Web of Science ®Google Scholar
• HOMIK J, CRANNEY A, SHEA B et al.: Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst. Rev (2000) CD001347.
   Google Scholar
• GREEN TJ, ISSENMAN RM and JACOBSON K: Patients diets and preferences in a pediatric population with inflammatory bowel disease. Can. Gastroenterol (1998) 12:544–549.
   PubMedGoogle Scholar
• BERNSTEIN CN, AMENT M, ARTINIAN L, RIDGEWAY J, SHANAHAN F: Milk tolerance in adults with ulcerative colitis. Am. Gastroenterol (1994) 89:872–877.
   PubMed Web of Science ®Google Scholar
• PFEFFERKORN MD, FITZGERALD JF, CROFFIE JM et al.: Lactase deficiency: not more common in pediatric patients with inflammatory bowel disease than in patients with chronic abdominal pain. I Pediatr. Gastroenterol Nutr. (2002) 35:339–343.
   PubMedGoogle Scholar
• OLSSON R, DANIELSSON A, JARNEROT G et al.: Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology (1991) 100:1319–1323.
   PubMed Web of Science ®Google Scholar
• WILSCHANSKI M, CHAIT P, WADE JA et al.: Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology (1995) 22:1415–1422.
   PubMed Web of Science ®Google Scholar
• FELDSTEIN AE, PERRAULT J, EL YOUSSIF M et al.: Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology (2003) 38:210–217.
   Google Scholar
• ••Liver survival data in a relatively largecohort of children with PSC.
   Google Scholar
• OKOLICSANYI L, GROPPO M, FLOREANI A et al: Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig. Liver Dis. (2003) 35:325–331.
   PubMedGoogle Scholar
• LOFTUS EV Jr, AGUILAR HI, SANDBORN WJ et al.: Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology (1998) 27:685–690.
   PubMedGoogle Scholar
• BROOME U, LOFBERG R, VERESS B, ERIKSSON LS: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology (1995) 22:1404–1408.
   PubMed Web of Science ®Google Scholar
• BARABINO A, TEGALDO L, CASTELLANO E et al.: Severe attack of ulcerative colitis in children: retrospective clinical survey. Dig. Liver Dis. (2002) 34:44–49.
   PubMedGoogle Scholar
• DICKINSON RJ, ASHTON MG, AXON AT et al: Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology (1980) 79:1199–1204.
   PubMed Web of Science ®Google Scholar
• RIZZELLO F, GIONCHETTI P, VENTURI A, CAMPIERI M: Review article: medical treatment of severe ulcerative colitis. Ailment. Pharmacol Ther: (2003) 17\(Suppl. 2): 7–10.
   Google Scholar
• MANTZARIS GJ, PETRAKI K, ARCHAVLIS E et al.: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand. Gastroenterol (2001) 36:971–974.
   PubMed Web of Science ®Google Scholar
• DICKINSON RJ, O'CONNOR HJ, PINDER I et al: Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut (1985) 26:1380–1384.
   PubMed Web of Science ®Google Scholar
• BURKE DA, AXON AT, CLAYDEN SA et al.: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment. Pharmacol Ther. (1990) 4:123–129.
   PubMed Web of Science ®Google Scholar
• GIONCHETTI P, RIZZELLO F, FERRIERI A et al: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig. Dis. ScL (1999) 44:1220–1221.
   PubMed Web of Science ®Google Scholar
• EADEN JA, MAYBERRY JF: Colorectal cancer complicating ulcerative colitis: a review. Am.! Gastroenterol (2000) 95:2710–2719.
   PubMedGoogle Scholar
• •A review of the implications of long-standing UC.
   Google Scholar
• EADEN J, ABRAMS K, EKBOM A, JACKSON E, MAYBERRY J: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment. Pharmacol Ther. (2000) 14:145–153.
   PubMed Web of Science ®Google Scholar
• LIM CH, DIXON ME VAIL A et al: Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut (2003) 52:1127–1132.
   PubMed Web of Science ®Google Scholar
• ••Controversy surrounds the role ofendoscopic surveillance for carcinoma in UC.
   Google Scholar
• NICHOLLS RJ: Review article: ulcerative colitis - surgical indications and treatment. Aliment. Pharmacol Ther. (2002) 16\(Suppl. 4):25–28.
   Google Scholar
• MAHADEVAN U, SANDBORN WJ: Diagnosis and management of pouchitis. Gastroenterology (2003) 124:1636–1650.
   PubMed Web of Science ®Google Scholar
• FONKALSRUD EW, THAKUR A, BEANES S: Ileoanal pouch procedures in children. Pediatr. Surg. (2001) 36:1689–1692.
   Google Scholar
• RINTALA RJ, LINDAHL HG: Proctocolectomy and J-pouch ileo-anal anastomosis in children. I Pediatr. Surg. (2002) 37:66–70.
   PubMed Web of Science ®Google Scholar
• ALEXANDER F, SARIGOL S, DIFIORE J et al.: Fate of the pouch in 151 pediatric patients after ileal pouch anal anastomosis. Pediatr. Surg. (2003) 38:78–82.
   Google Scholar
• ••Recent data suggesting that ileoanalanastomosis is well tolerated by children.
   Google Scholar
• STAVLO PL, LIBSCH KD, RODEBERG DA, MOIR CR: Pediatric ileal pouch-anal anastomosis: Functional outcomes and quality of life.' Pediatr. Surg. (2003) 38:935–939.
   PubMed Web of Science ®Google Scholar
• NICHOLLS S, VIEIRA MC, MAJROWSKI WH et al.: Linear growth after colectomy for ulcerative colitis in childhood. Pediatr. Gastroenterol Nutr. (1995) 21:82–86.
   PubMedGoogle Scholar
• ROBB BW, GANG GI, HERSHKO DD et al.: Restorative proctocolectomy with ileal pouch-anal anastomosis in very young patients with refractory ulcerative colitis. Pediatr. Surg. (2003) 38:863–867.
   Google Scholar